GENIE - Genetic and Environmental Risk for Alzheimer's Disease

Introduction

The Genetic and Environmental Risk for Alzheimer's Disease (GENIE) is a multi-site neuroimaging genetics consortium that investigates how genetic variants influence brain structure, function, and the risk of developing [Alzheimer's Disease](/diseases/alzheimers-disease).[@carroll2011] GENIE combines genetic data with neuroimaging to understand the biological pathways from genes to brain changes to clinical symptoms.

Study Design

Introduction

The Genetic and Environmental Risk for Alzheimer's Disease (GENIE) is a multi-site neuroimaging genetics consortium that investigates how genetic variants influence brain structure, function, and the risk of developing [Alzheimer's Disease](/diseases/alzheimers-disease).[@carroll2011] GENIE combines genetic data with neuroimaging to understand the biological pathways from genes to brain changes to clinical symptoms.

Study Design

GENIE employs a multi-site, case-control and family-based design:[@potkin2009]

• Case-Control Cohort: Genetically characterized AD patients and healthy controls
• Family Cohort: Multigenerational families with high AD prevalence
• Longitudinal Arm: Follow-up imaging to track brain changes over time

Key Objectives

Data Collection

Genetic Data

• Genome-wide Genotyping: SNP arrays for common variant analysis
• Whole Genome Sequencing: Rare variant discovery
• APOE Genotyping: Focused analysis of the major AD risk allele

Imaging Modalities

GENIE collects multiple imaging modalities:[@fleisher2005]

• Structural MRI: Brain volume, hippocampal volume, cortical thickness
• FDG-PET: Glucose metabolism as a marker of neuronal function
• Amyloid PET: In vivo amyloid burden measurement
• Functional MRI: Brain connectivity patterns

Clinical Data

• Cognitive Testing: Comprehensive neuropsychological batteries
• Clinical Diagnosis: AD, MCI, and healthy control classifications
• Demographic Information: Age, sex, education, family history

Major Findings

APOE Effects on the Brain

GENIE demonstrated that [APOE](/genes/apoe) ε4 carriers show characteristic patterns of hippocampal atrophy and reduced glucose metabolism, even before clinical symptoms[@soininen2022]

Genetic Imaging Endophenotypes

The consortium identified novel genetic loci associated with hippocampal volume, providing insights into the biology of brain aging[@potkin2009]

Brain Imaging Biomarkers

GENIE contributed to validating neuroimaging biomarkers for preclinical AD, including hippocampal atrophy rates and FDG-PET hypometabolism[@langbaum2013]

Risk Prediction Models

The consortium developed polygenic risk scores that combine multiple genetic variants to predict brain changes and cognitive decline[@reiman2012]

Impact on Research

GENIE has significantly advanced the field by:[@carroll2011]

• Establishing neuroimaging as a powerful tool for genetic studies
• Identifying novel genetic variants affecting brain structure
• Enabling gene-set enrichment analyses for AD
• Supporting the development of personalized medicine approaches

Participating Institutions

GENIE involves collaboration among multiple research centers:

• Banner Alzheimer's Institute
• University of Arizona
• Mayo Clinic Arizona
• University of Pennsylvania
• Washington University in St. Louis

Data Access

GENIE data are available through:[@caselli2012]

• The Laboratory of Neuro Imaging (LONI) archive
• The Accelerating Medicines Partnership for Alzheimer's Disease (AMP-AD)
• Collaborative analysis agreements

See Also

• [Alzheimer's Disease](/diseases/alzheimers-disease)
• [APOE](/genes/apoe)
• [ADNI](/projects/adni)
• [Amyloid PET Imaging](/biomarkers/amyloid-pet-imaging)

External Links

• [GENIE Publications](https://www.ncbi.nlm.nih.gov/pmc/?term=GENIE+Alzheimer%27s)
• [Accelerating Medicines Partnership - AD](https://nih.gov/AMP-AD)

References